Cotadutide – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

Cotadutide is a dual GLP-1 and glucagon receptor agonist from AstraZeneca, investigated for type 2 diabetes, fatty liver disease, and obesity. It is a balanced co-agonist (about 5:1 GLP-1 to glucagon). The GLP-1 component does the usual incretin work: insulin release, glucagon suppression, appetite reduction. The glucagon component independently raises energy expenditure and lipolysis, theoretically adding fat-burning on top of appetite suppression. Phase 2 trials showed strong glycemic and weight effects. AstraZeneca de-prioritized it in 2023 in favor of other pipeline assets, leaving its commercial future unclear. The dual-agonist concept lives on in mazdutide and survodutide. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

63/100

Dual GLP-1/glucagon agonist with a genuine NASH thesis and real Phase 2 metabolic signal

Cotadutide sits in an interesting position in the incretin landscape. It’s not tirzepatide, it’s not retatrutide, and it was never meant to be. What it is: a carefully balanced dual GLP-1/glucagon agonist with a specific research thesis around hepatic fat clearance that pure GLP-1 drugs can’t match on mechanism.

The core design is a roughly 30 amino acid peptide with a C16 fatty acid extension, biased approximately 5:1 GLP-1:glucagon at receptor. The GLP-1 side handles what you’d expect: glucose-dependent insulin secretion, glucagon suppression, appetite attenuation. The glucagon component is where it gets interesting. Glucagon receptor activation in the liver directly drives fatty acid oxidation and lipolysis independent of the GLP-1 effects. Thats the NASH thesis: if you can drive hepatic fat clearance through a mechanism that pure GLP-1 agonism doesnt fully access, you get additive benefit at the liver. Phase 2 data (NCT03205761 and related trials from the AstraZeneca program) showed both superior weight loss versus matched-dose GLP-1 monoagonist controls and meaningful hepatic fat reduction on MRI-PDFF, which is the endpoint NASH investigators actually care about.

We think the mechanism promise here is genuine. The dual-target design isn’t just stacking two agonists; the glucagon axis contributes something mechanistically distinct to the hepatic fat story. That makes cotadutide more than a me-too in the incretin space, even with tirzepatide and retatrutide in the picture. The GIP/GLP-1 axis that tirzepatide exploits and the triple agonism retatrutide is chasing are complementary programs, not direct replacements for this specific hepatic mechanism.

What we don’t love: differentiation is real but incomplete. Retatrutide already includes glucagon co-agonism as part of a more ambitious mechanism stack, which raises the question of where cotadutide fits long-term if triple agonists clear Phase 3. The NASH indication might be the answer. Resmetirom (a THR-beta agonist) is now the first approved MASH therapy, but combination approaches pairing a metabolic backbone compound with a thyroid receptor modulator are an obvious next direction, and cotadutide is a better-characterized reference for the GLP-1/glucagon axis than most alternatives in that conversation.

As a research tool, cotadutide earns its place as the reference dual GLP-1/glucagon agonist for metabolic research programs. If you want to specifically dissect what glucagon co-agonism contributes to a GLP-1 backbone in hepatic and metabolic endpoints, this is the probe you reach for. Evidence base is Phase 2 with Phase 3 ongoing, methodology is solid, and the AstraZeneca program has been transparent with the data. Honest score: real signal, useful probe, genuine mechanism differentiation, but not yet at the top tier of this class until Phase 3 reads out.

Novelty: 62
Mechanism promise: 76
In-category differentiation: 55
Evidence quality: 57
Translational signal: 63
Research bench value: 63

Rationale Scores well on mechanism (dual hepatic-targeted design is mechanistically distinct from pure GLP-1 agonism) and translational signal (Phase 2 data shows HbA1c, weight, and hepatic fat reduction vs matched GLP-1 controls), but differentiation is moderated by retatrutide’s triple agonism and the Phase 3 readout is still pending. Placed novel-promising given the NASH-specific research angle and genuine bench utility as the reference GLP-1/glucagon dual agonist probe.

GLP-1 / glucagon dual receptor agonist

A dual GLP-1 and glucagon receptor agonist; investigated for type 2 diabetes, NASH, and obesity.

Abstract

Cotadutide (MEDI0382; CAS 2125247-22-1; modified peptide with glucagon backbone and GLP-1 modifications; approximately 30 amino acid peptide with C16 fatty acid extension; molecular weight approximately 4140 Da) is a dual GLP-1/glucagon receptor agonist developed at AstraZeneca for type 2 diabetes, non-alcoholic steatohepatitis (NASH), and obesity. The compound is a balanced co-agonist (approximately 5:1 GLP-1:glucagon ratio at receptor). The GLP-1 component drives glucose-dependent insulin secretion, glucagon suppression, and appetite reduction; the glucagon component independently increases hepatic fatty acid oxidation, energy expenditure, and lipolysis. Phase 2 trials demonstrated superior weight loss and HbA1c reduction compared to GLP-1 monoagonists at matched dose, with hepatic fat reduction supporting the NASH indication. Plasma half-life supports once-daily subcutaneous dosing; phase 3 development is ongoing. Used as a reference dual GLP-1/glucagon agonist in metabolic research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-295Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.